N/A N=158 Self-discontinuation of a Transurethral Catheter
Postoperative Urinary Retention
Primary: Number of Participants With Postoperative Urinary Retention — 11; 11 Participants — p=0.5
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=68 Ceramic-on-ceramic THA for Post-traumatic Hip Osteoarthritis After Acetabular Fracture
Hip Osteoarthritis · Post-traumatic Osteoarthritis
Primary: Survival Rates of the Hip Implants — 96.3 percentage of non-revised implants
Phase 4 N=36 Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery.
Nerve Block · General Anesthesia · Spinal Anesthesia
Primary: Time Until Patient is Ready for Discharge From Post-Anesthesia Care Unit (PACU) to Home. — 81; 43.5 Minutes
N/A N=20 Lipoprotein Apheresis in Refractory Angina Study
Refractory Angina · Raised Lipoprotein(a)>50mg/dL or >500mg/L
Primary: Changes in Quantitative Myocardial Perfusion Measured by Stress/Rest Cardiovascular Magnetic Resonance Imaging — 0.47; -0.16 ratio — p=0.001
N/A N=98 Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation
Mild Cognitive Impairment · Metabolic Syndrome
Primary: MoCA (Montreal Cognitive Assessment) — 28.38; 20.22 score on a scale — p=<0.0001
Phase 4 N=166 Immunologic Response to Influenza Vaccination in Children and Adolescents
Influenza, Human · Immune Response
Primary: Determining Seroconversion Response - Change in HI Titers From Pre- to Post Vaccination — 20; 14; 9; 11 Participants — p=0.28
Phase 2 N=66 Study Examining PrEP-001 in Healthy Subjects
Influenza A H3N2
Primary: Primary Efficacy Endpoint: The Area Under the Curve (AUC) of Total Symptom Score From Day 1 (Post Viral Challenge) to Day 8 (Quarantine Discharge). — 17956.5; 4502.6…
Phase 4 N=59 Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
Refractory Cutaneous T-cell Lymphoma
Primary: Number of Participants With Tumor Response (Complete Response [CR], Clinical Complete Response [CCR], and Partial Response [PR]) in up to 5 Index Lesions as Determined…
N/A N=302 I-ACT With Check Yourself
Adolescent Behavior
Primary: Number of Health Risk Behaviors — 2.23; 2.62 score on a scale
Phase 4 N=60 Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure
Heart Failure
Primary: Weight Change Over 48 Hours — -4.6; -5.8; -4.1 kg
N/A N=204 Permanent Versus Absorbable Colpopexy Trial
Pelvic Organ Prolapse
Primary: Number of Participants With Vaginal Mesh or Suture Exposure — 5; 8 Participants — p=0.30
N/A N=4,240 Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.
Lung Neoplasms
Primary: Number of Participants With Prevalence of Anaplastic Lymphoma Kinase (ALK) Biomarker — 45; 1346; 21; 38 Participants
N/A N=162 Comparing Early Versus Elective Colonoscopy
Acute Lower Gastrointestinal Bleeding
Primary: Stigmata of Recent Hemorrhage (SRH) Identification Rate — 17; 17 Participants
N/A N=120 Shockwave Coronary Lithoplasty® Study (Disrupt CAD II)
Coronary Artery Disease
Primary: Number of Participants With In-hospital Major Adverse Cardiac Events (MACE) — 7 Participants
Phase 1 N=18 Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging
Rheumatoid Arthritis
Primary: Localization of Tc 99m Tilmanocept by Planar and SPECT/CT Imaging in Subjects With Active RA and Concordance With Swollen/Tender Joints — 0; 0; 30; 35 Joints